Figure 2.

Comparative Kaplan-Meier analysis of progression-free survival in NSCLC patients between the AM group and PM groups. AP, pemetrexed plus platinum; CI, confidence interval; HR, hazard ratio; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer.